Suppr超能文献

Could menopause drug fezolinetant show promise for vasomotor symptoms associated with androgen deprivation therapy?

作者信息

Qin Kirby R, Mertens Eveline, Tempo Jake A, Perera Marlon, Brennan Janelle

机构信息

Department of Urology, Bendigo Health, Bendigo, VIC, Australia.

School of Rural Health, Monash University, Bendigo, VIC, Australia.

出版信息

Transl Androl Urol. 2024 May 31;13(5):920-922. doi: 10.21037/tau-24-12. Epub 2024 May 15.

Abstract
摘要

相似文献

1
Could menopause drug fezolinetant show promise for vasomotor symptoms associated with androgen deprivation therapy?
Transl Androl Urol. 2024 May 31;13(5):920-922. doi: 10.21037/tau-24-12. Epub 2024 May 15.
3
Fezolinetant: A New Nonhormonal Treatment for Vasomotor Symptoms.
J Pharm Technol. 2023 Dec;39(6):291-297. doi: 10.1177/87551225231198700. Epub 2023 Sep 16.
4
Effectiveness and safety of fezolinetant in alleviating vasomotor symptoms linked to Menopause.: A systematic review and Meta-Analysis.
Eur J Obstet Gynecol Reprod Biol. 2024 Jun;297:142-152. doi: 10.1016/j.ejogrb.2024.04.017. Epub 2024 Apr 15.
5
Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial.
Obstet Gynecol. 2023 Apr 1;141(4):737-747. doi: 10.1097/AOG.0000000000005114. Epub 2023 Mar 9.
6
Effects of neurokinin 3 receptor antagonist fezolinetant on hot flash-like symptoms in ovariectomized rats.
Eur J Pharmacol. 2021 Aug 15;905:174207. doi: 10.1016/j.ejphar.2021.174207. Epub 2021 May 25.
8
Fezolinetant: A Potential Treatment for Moderate to Severe Vasomotor Symptoms of Menopause.
touchREV Endocrinol. 2023 Nov;19(2):69-72. doi: 10.17925/EE.2023.19.2.13. Epub 2023 Jun 15.
9
A Novel Nonhormonal Treatment for Vasomotor Symptoms of Menopause.
Nurs Womens Health. 2024 Feb;28(1):80-84. doi: 10.1016/j.nwh.2023.11.005. Epub 2023 Dec 28.

本文引用的文献

2
Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial.
Obstet Gynecol. 2023 Apr 1;141(4):737-747. doi: 10.1097/AOG.0000000000005114. Epub 2023 Mar 9.
4
Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT.
J Clin Endocrinol Metab. 2023 Jul 14;108(8):1981-1997. doi: 10.1210/clinem/dgad058.
5
7
A Neural Circuit Underlying the Generation of Hot Flushes.
Cell Rep. 2018 Jul 10;24(2):271-277. doi: 10.1016/j.celrep.2018.06.037.
8
International survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries.
ESMO Open. 2016 Mar 18;1(2):e000040. doi: 10.1136/esmoopen-2016-000040. eCollection 2016.
9
Effects of Testosterone and Estradiol Deficiency on Vasomotor Symptoms in Hypogonadal Men.
J Clin Endocrinol Metab. 2016 Sep;101(9):3479-86. doi: 10.1210/jc.2016-1612. Epub 2016 Jun 14.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验